HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Humacyte, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.40−0.03 (-6.50%)
Close on Oct 19, 2026
- Market cap
- $93.93M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.3189 (−76.68%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Humacyte, Inc. grew revenue 159.3% to $2.12M over the twelve months to Jun 30, 2026. Free cash flow was -$97.56M.
Revenue
$2.12M
+159.3% vs. a year earlier
Operating income
-$111.16M
TTM Q2 2026
Free cash flow
-$97.56M
TTM Q2 2026
EPS, diluted
-$0.49
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $93.93M
- P/E ratio
- –
- Price to sales
- 44.29
- Price to book
- 3.00
- Dividend yield
- –
- Free cash flow yield
- -103.86%
Fundamentals
- Revenue
- $2.12M
- Net income
- -$96.74M
- EPS, diluted
- -$0.49
- Free cash flow
- -$97.56M
- Book value per share
- $0.13
- Diluted shares
- 234M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$2.12M+159.3% YoY
Gross profit
-$10.49M-2390.4% YoY
Operating income
-$111.16M
Net income
-$96.74M
EPS, diluted
-$0.49
Free cash flow
-$97.56M
Reported periodTrailing twelve months